616229-75-5Relevant academic research and scientific papers
Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors
Lawrence, Harshani R.,Martin, Mathew P.,Luo, Yunting,Pireddu, Roberta,Yang, Hua,Gevariya, Harsukh,Ozcan, Sevil,Zhu, Jin-Yi,Kendig, Robert,Rodriguez, Mercedes,Elias, Roy,Cheng, Jin Q.,Sebti, Sa?d M.,Schonbrunn, Ernst,Lawrence, Nicholas J.
supporting information, p. 7392 - 7416 (2012/11/07)
The o-carboxylic acid substituted bisanilinopyrimidine 1 was identified as a potent hit (Aurora A IC50 = 6.1 ± 1.0 nM) from in-house screening. Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are critical for potent activity. X-ray crystallography studies revealed that compound 1 is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation. Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation. B-Ring modifications were undertaken to improve the solubility and cell permeability. Compounds such as 9m with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.
AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF
-
Page/Page column 61, (2012/10/18)
Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: Identification and optimisation of substituted 2,4-bis anilino pyrimidines
Breault, Gloria A.,Ellston, Rebecca P. A.,Green, Stephen,James, S. Russell,Jewsbury, Philip J.,Midgley, Catherine J.,Pauptit, Richard A.,Minshull, Claire A.,Tucker, Julie A.,Pease, J. Elizabeth
, p. 2961 - 2966 (2007/10/03)
Through chemical modification and X-ray crystallography we identified the 2,4-bis anilino pyrimidines as potent inhibitors of CDK4. Herein, we describe the optimisation of this series.
